Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome

Clinica Chimica Acta

Volumn 412, Issue 19-20, 2011, Pages 1835-1841

  Liang, Kae Woei ^a,b   Lee, Wen Jane ^a,c   Lee, I Te ^a,b,d   Lee, Wen Lieng ^a,b   Lin, Shih Yi ^a,b   Hsu, Shih Lan ^a   Wan, Chu Jen ^a   Yu, Chen Yuan ^a   Tsai, I Chen ^a,b   Fu, Chia Po ^a   Ting, Chih Tai ^a,b   Sheu, Wayne H H ^a,b,d,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TUNGHAI UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Metabolic syndrome; Monocyte chemotactic protein 1 (MCP 1); Obesity; Paraoxonase 1 (PON1); Weight loss

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; KINESIOTHERAPY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; ARYLDIALKYLPHOSPHATASE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 79960652191     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.018     Document Type: Article

References (42)

1. van Himbergen T.M., van Tits L.J., Roest M., Stalenhoef A.F. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006, 64:34-38.
2. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
3. van Himbergen T.M., van der Schouw Y.T., Voorbij H.A., et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008, 199:408-414.
4. Mackness B., Mackness M.I., Arrol S., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139:341-349.
5. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1812-1818.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421.
7. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
8. Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Kahn R.A. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109:551-556.
9. Gu D., Reynolds K., Wu X., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005, 365:1398-1405.
10. Lee W.Y., Park J.S., Noh S.Y., Rhee E.J., Kim S.W., Zimmet P.Z. Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004, 65:143-149.
11. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino R.B., Wilson P.W.F. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110:380-385.
12. Koh K.K., Han S.H., Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978-1985.
13. Liang K.W., Lee W.J., Lee W.L., Chen Y.T., Ting C.T., Sheu W.H. Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clin Chim Acta 2008, 388:41-45.
14. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
15. Marroquin O.C., Kip K.E., Kelley D.E., et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004, 109:714-721.
16. Malik S., Wong N.D., Franklin S., Pio J., Fairchild C., Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005, 28:690-693.
17. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132.
18. Roberts C.K., Ng C., Hama S., Eliseo A.J., Barnard R.J. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006, 101:1727-1732.
19. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
20. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
21. Rector R.S., Warner S.O., Liu Y., et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 2007, 293:E500-E506.
22. Cambuli V.M., Musiu M.C., Incani M., et al. Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J Clin Endocrinol Metab 2008, 93:3051-3057.
23. Bajnok L., Csongradi E., Seres I., et al. Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis 2008, 197:363-367.
24. Senti M., Tomas M., Fito M., et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003, 88:5422-5426.
25. Tabur S., Torun A.N., Sabuncu T., et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol 2010, 162:535-541.
26. Tong P.C., Kong A.P., So W.Y., et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007, 30:1206-1211.
27. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
28. Sheu W.H., Chang T.M., Lee W.J., et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring) 2008, 16:1033-1038.
29. Sheu W.H., Chin H.M., Lee W.J., Wan C.J., Su H.Y., Lang H.F. Prospective evaluation of folic acid supplementation on plasma homocysteine concentrations during weight reduction: a randomized, double-blinded, placebo-controlled study in obese women. Life Sci 2005, 76:2137-2145.
30. Liang K.W., Sheu W.H., Lee W.L., et al. Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol 2008, 129:76-80.
31. Liang K.W., Lee W.J., Lee W.L., Ting C.T., Sheu W.H. Decreased ratio of high-molecular-weight to total adiponectin is associated with angiographic coronary atherosclerosis severity but not restenosis. Clin Chim Acta 2009, 405:114-118.
32. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007, 191:397-402.
33. Aslan M., Nazligul Y., Horoz M., et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008, 196:270-274.
34. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
35. Fuhrman B., Volkova N., Aviram M. Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 2010, 26:359-366.
36. Rosenblat M., Karry R., Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006, 187:74-81.
37. Bajnok L., Seres I., Varga Z., et al. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism 2007, 56:1542-1549.
38. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33.
39. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
40. Kotani K., Sakane N., Sano Y., et al. Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. J Clin Biochem Nutr 2009, 45:329-334.
41. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
42. Cao H., Girard-Globa A., Berthezene F., Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. J Lipid Res 1999, 40:133-139.